Published in Glycobiology on June 18, 2009
Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One (2013) 1.04
Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem (2012) 1.00
Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One (2013) 0.92
Structural aspects of binding of α-linked digalactosides to human galectin-1. Glycobiology (2011) 0.86
Binding of Toxoplasma gondii glycosylphosphatidylinositols to galectin-3 is required for their recognition by macrophages. J Biol Chem (2010) 0.85
Structural features for α-galactomannan binding to galectin-1. Glycobiology (2011) 0.83
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo. Leukemia (2016) 0.81
Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain. Glycobiology (2016) 0.78
Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines. Cancers (Basel) (2011) 0.77
Low or No Inhibitory Potency of the Canonical Galectin Carbohydrate-binding Site by Pectins and Galactomannans. J Biol Chem (2016) 0.76
Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1. J Pharmacol Exp Ther (2012) 0.76
Intra- and intermolecular interactions of human galectin-3: assessment by full-assignment-based NMR. Glycobiology (2016) 0.76
Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-Dependent Interactions in Cancer. Front Oncol (2016) 0.75
NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR (1995) 93.94
NMR View: A computer program for the visualization and analysis of NMR data. J Biomol NMR (1994) 22.42
In vivo imaging of membrane-associated glycans in developing zebrafish. Science (2008) 5.45
Galectins as modulators of tumour progression. Nat Rev Cancer (2005) 5.30
Galectins: a family of animal beta-galactoside-binding lectins. Cell (1994) 3.99
Apoptosis of T cells mediated by galectin-1. Nature (1995) 3.54
Tumour vascular targeting. Nat Rev Cancer (2005) 2.56
Exploring the structural diversity of mammalian carbohydrates ("glycospace") by statistical databank analysis. ACS Chem Biol (2007) 2.42
Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci (2004) 2.31
Clusters, bundles, arrays and lattices: novel mechanisms for lectin-saccharide-mediated cellular interactions. Curr Opin Struct Biol (2002) 2.27
Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A (2006) 2.26
Functions of cell surface galectin-glycoprotein lattices. Curr Opin Struct Biol (2007) 1.97
Possible roles of tumor-associated carbohydrate antigens. Cancer Res (1996) 1.90
Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J Biol Chem (2006) 1.73
Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J Immunol (1999) 1.69
Sweet 'n' sour: the impact of differential glycosylation on T cell responses. Nat Immunol (2002) 1.65
Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J Exp Med (1997) 1.64
Galectin-3 induces death of Candida species expressing specific beta-1,2-linked mannans. J Immunol (2006) 1.61
Growth-regulatory human galectin-1: crystallographic characterisation of the structural changes induced by single-site mutations and their impact on the thermodynamics of ligand binding. J Mol Biol (2004) 1.57
Noncovalent cell surface engineering: incorporation of bioactive synthetic glycopolymers into cellular membranes. J Am Chem Soc (2008) 1.41
Galectin-1 interacts with the {alpha}5{beta}1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J Biol Chem (2005) 1.37
beta-1,2-linked oligomannosides from Candida albicans bind to a 32-kilodalton macrophage membrane protein homologous to the mammalian lectin galectin-3. Infect Immun (2000) 1.31
Crosslinking of mammalian lectin (galectin-1) by complex biantennary saccharides. Nat Struct Biol (1994) 1.30
Paradigms for glycan-binding receptors in cell adhesion. Curr Opin Cell Biol (2007) 1.24
Structure and functional analysis of the fungal galectin CGL2. Structure (2004) 1.20
A recipe for designing water-soluble, beta-sheet-forming peptides. Protein Sci (1996) 1.15
Crystal structure of the galectin-9 N-terminal carbohydrate recognition domain from Mus musculus reveals the basic mechanism of carbohydrate recognition. J Biol Chem (2006) 1.13
A pulsed-field gradient NMR study of bovine pancreatic trypsin inhibitor self-association. Biochemistry (1997) 1.11
Heparan sulfate proteoglycans: a GAGgle of skeletal-hematopoietic regulators. Dev Dyn (2008) 1.10
Heparin dodecasaccharide binding to platelet factor-4 and growth-related protein-alpha. Induction of a partially folded state and implications for heparin-induced thrombocytopenia. J Biol Chem (1999) 1.03
Demonstration of protein-protein interaction specificity by NMR chemical shift mapping. Protein Sci (1997) 0.97
1H, 13C, and 15N backbone and side-chain chemical shift assignments for the 29 kDa human galectin-1 protein dimer. Biomol NMR Assign (2008) 0.96
Hierarchical assembly of model cell surfaces: synthesis of mucin mimetic polymers and their display on supported bilayers. J Am Chem Soc (2007) 0.96
Selective recognition of mannose by the human eosinophil Charcot-Leyden crystal protein (galectin-10): a crystallographic study at 1.8 A resolution. Biochemistry (1999) 0.95
The carbohydrate-binding domain on galectin-1 is more extensive for a complex glycan than for simple saccharides: implications for galectin-glycan interactions at the cell surface. Biochem J (2009) 0.94
NMR study of the galactomannans of Trichophyton mentagrophytes and Trichophyton rubrum. Biochem J (1997) 0.89
Using pulse field gradient NMR diffusion measurements to define molecular size distributions in glycan preparations. Carbohydr Res (2009) 0.86
On the galactosyl distribution of commercial galactomannans. Carbohydr Res (2000) 0.84
Carbohydrate-induced modulation of cell membrane. VIII. Agglutination with mammalian lectin galectin-1 increases osmofragility and membrane fluidity of trypsinized erythrocytes. FEBS Lett (2006) 0.83
Terminal alpha-linked galactose rather than N-acetyl lactosamine is ligand for bovine heart galectin-1 in N-linked oligosaccharides of glycoproteins. J Mol Recognit (2002) 0.83
Interaction profile of galectin-5 with free saccharides and mammalian glycoproteins: probing its fine specificity and the effect of naturally clustered ligand presentation. Glycobiology (2006) 0.81
Cell surface glycosylation diversity of embryonic thymic tissues. Acta Histochem (2007) 0.78
Structural determination of an exocellular mannan from Rhodotorula mucilaginosa YR-2 using ab initio assignment of proton and carbon NMR spectra. Carbohydr Res (2001) 0.77
A water-soluble galactomannan from the seeds of Phoenix dactylifera L. Carbohydr Res (2001) 0.76
Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A (2006) 2.26
Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med (2009) 2.15
Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res (2007) 2.13
Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood (2006) 1.82
Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J (2006) 1.76
Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J (2007) 1.23
The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res (2003) 1.22
Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett (2010) 1.16
Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer (2005) 1.13
Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res (2006) 1.11
The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J (2002) 1.09
Promotion of peptide antimicrobial activity by fatty acid conjugation. Bioconjug Chem (2004) 1.07
Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem (2004) 1.06
Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One (2013) 1.04
Acylation of SC4 dodecapeptide increases bactericidal potency against Gram-positive bacteria, including drug-resistant strains. Biochem J (2004) 1.04
Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett (2003) 1.03
Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J Natl Cancer Inst (2006) 1.03
Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene. Bioconjug Chem (2010) 1.02
Lactose binding to galectin-1 modulates structural dynamics, increases conformational entropy, and occurs with apparent negative cooperativity. J Mol Biol (2010) 1.02
CXC and CC chemokines form mixed heterodimers: association free energies from molecular dynamics simulations and experimental correlations. J Biol Chem (2008) 1.02
Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem (2012) 1.00
Metastin (KiSS-1) mimetics identified from peptide structure-activity relationship-derived pharmacophores and directed small molecule database screening. J Med Chem (2007) 0.98
A journey in structure-based drug discovery: from designed peptides to protein surface topomimetics as antibiotic and antiangiogenic agents. Acc Chem Res (2007) 0.98
Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res (2011) 0.98
1H, 13C, and 15N backbone and side-chain chemical shift assignments for the 29 kDa human galectin-1 protein dimer. Biomol NMR Assign (2008) 0.96
Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Lett (2008) 0.95
The carbohydrate-binding domain on galectin-1 is more extensive for a complex glycan than for simple saccharides: implications for galectin-glycan interactions at the cell surface. Biochem J (2009) 0.94
Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J Control Release (2011) 0.92
Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil Steril (2005) 0.91
Topomimetics of amphipathic beta-sheet and helix-forming bactericidal peptides neutralize lipopolysaccharide endotoxins. J Med Chem (2006) 0.90
Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. Biochem J (2003) 0.89
Anginex-conjugated liposomes for targeting of angiogenic endothelial cells. Bioconjug Chem (2007) 0.87
The nociceptin pharmacophore site for opioid receptor binding derived from the NMR structure and bioactivity relationships. J Biol Chem (2004) 0.87
Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay. Int J Clin Oncol (2007) 0.87
Tumour thermotolerance, a physiological phenomenon involving vessel normalisation. Int J Hyperthermia (2011) 0.87
Using pulse field gradient NMR diffusion measurements to define molecular size distributions in glycan preparations. Carbohydr Res (2009) 0.86
Structural aspects of binding of α-linked digalactosides to human galectin-1. Glycobiology (2011) 0.86
NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents. Mol Cancer Ther (2009) 0.85
Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochem Biophys Res Commun (2006) 0.84
Heat capacities and a snapshot of the energy landscape in protein GB1 from the pre-denaturation temperature dependence of backbone NH nanosecond fluctuations. J Mol Biol (2003) 0.83
Measuring protein self-diffusion in protein-protein mixtures using a pulsed gradient spin-echo technique with WATERGATE and isotope filtering. J Magn Reson (2004) 0.83
Structural features for α-galactomannan binding to galectin-1. Glycobiology (2011) 0.83
(1)H, (13)C, and (15)N backbone and side-chain chemical shift assignments for the 36 proline-containing, full length 29 kDa human chimera-type galectin-3. Biomol NMR Assign (2014) 0.83
Discovery and development of anti-angiogenic peptides: A structural link. Angiogenesis (2003) 0.83
Cloning an artificial gene encoding angiostatic anginex: From designed peptide to functional recombinant protein. Biochem Biophys Res Commun (2005) 0.82
Probing structure-activity relationships in bactericidal peptide betapep-25. Biochem J (2008) 0.82
Comparison of (13)C(alpha)H and (15)NH backbone dynamics in protein GB1. Protein Sci (2003) 0.82
NMR solution structure of the angiostatic peptide anginex. Biochim Biophys Acta (2007) 0.82
Aqueous gel formation of a synthetic peptide derived from the beta-sheet domain of platelet factor-4. Biomacromolecules (2002) 0.81
A simple method to measure 13CH2 heteronuclear dipolar cross-correlation spectral densities. J Magn Reson (2004) 0.79
Lactose binding to human galectin-7 (p53-induced gene 1) induces long-range effects through the protein resulting in increased dimer stability and evidence for positive cooperativity. Glycobiology (2013) 0.79
The antiangiogenic properties of bactericidal/permeability-increasing protein (BPI). Ann Med (2002) 0.79
1H, 13C, and 15N backbone and side-chain chemical shift assignments for the 31 kDa human galectin-7 (p53-induced gene 1) homodimer, a pro-apoptotic lectin. Biomol NMR Assign (2011) 0.78
p16(INK4a) Peptide mimetics identified via virtual screening. Bioorg Med Chem Lett (2009) 0.78
Identification of novel drug targets for angiostatic cancer therapy; it takes two to tango. Curr Pharm Des (2007) 0.77
Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer. Invest New Drugs (2013) 0.77
Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1. J Pharmacol Exp Ther (2012) 0.76
Structure/function studies of an endotoxin-neutralizing peptide derived from bactericidal/permeability-increasing protein. Surgery (2004) 0.76
Protein dynamics using frequency-dependent order parameters from analysis of NMR relaxation data. J Magn Reson (2003) 0.76
Defining the potential of aglycone modifications for affinity/selectivity enhancement against medically relevant lectins: synthesis, activity screening, and HSQC-based NMR analysis. Chembiochem (2014) 0.76
Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with Pseudomonas aeruginosa. Biochim Biophys Acta (2013) 0.75
Protein lysine-Nζ alkylation and O-phosphorylation mediated by DTT-generated reactive oxygen species. Protein Sci (2013) 0.75
Synthesis and antitumor activity of new D-galactose-containing derivatives of doxorubicin. Carbohydr Res (2003) 0.75